MedPath

Testosterone

Generic Name
Testosterone
Brand Names
Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo
Drug Type
Small Molecule
Chemical Formula
C19H28O2
CAS Number
58-22-0
Unique Ingredient Identifier
3XMK78S47O
Background

Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism. Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.

Testosterone was isolated from samples and also synthesized in 1935.

Indication

Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.

Associated Conditions
Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism, Puberty, Delayed, Inoperable, metastatic Breast cancer
Associated Therapies
-

Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality

Phase 2
Completed
Conditions
Hypogonadism
Interventions
First Posted Date
2020-07-30
Last Posted Date
2022-11-29
Lead Sponsor
Lars Møller Pedersen
Target Recruit Count
7
Registration Number
NCT04492553
Locations
🇩🇰

Herlev University Hospital, Herlev, Denmark

🇩🇰

Copenhagen University Hospital, Copenhagen, Denmark

🇩🇰

Zealand University Hospital, Roskilde, Denmark

A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Phase 4
Completed
Conditions
Hypogonadism, Male
Hypogonadotropic Hypogonadism
Hypogonadism
Interventions
First Posted Date
2020-07-02
Last Posted Date
2023-08-01
Lead Sponsor
Endo Pharmaceuticals
Target Recruit Count
676
Registration Number
NCT04456296
Locations
🇺🇸

Endo Clinical Trial Site #22, Tucson, Arizona, United States

🇺🇸

Endo Clinical Trial Site #3, Oviedo, Florida, United States

🇺🇸

Endo Clinical Trial Site #27, Glen Burnie, Maryland, United States

and more 32 locations

Pharmacokinetics of a Novel Vaginal Delivery System for Testosterone and Dehydroepiandrosterone (DHEA)

First Posted Date
2019-05-30
Last Posted Date
2019-05-30
Lead Sponsor
Laboratorios Andromaco S.A.
Target Recruit Count
46
Registration Number
NCT03967964
Locations
🇨🇱

Instituto de Investigación Materno Infantil (IDIMI) - Maternidad Hospital San Borja (HCSBA), Santiago, Chile

Testosterone Therapy in Castration Resistant Prostate Cancer

Early Phase 1
Active, not recruiting
Conditions
Prostate Cancer
Castration-Resistant Prostate Cancer
Interventions
Drug: Transdermal Testosterone
Drug: Standard of Care, Enzalutamide
First Posted Date
2018-11-08
Last Posted Date
2024-08-19
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
30
Registration Number
NCT03734653
Locations
🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.

Phase 4
Completed
Conditions
Hypogonadism
Obesity
Interventions
First Posted Date
2018-08-07
Last Posted Date
2018-08-07
Lead Sponsor
University Medical Centre Ljubljana
Target Recruit Count
30
Registration Number
NCT03619330
Locations
🇸🇮

University Medical Center Ljubljana, Ljubljana, Slovenia

TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

Phase 4
Completed
Conditions
Klinefelter Syndrome
Interventions
First Posted Date
2017-10-30
Last Posted Date
2022-05-06
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
72
Registration Number
NCT03325647
Locations
🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

Effects of Testosterone and Fat Utilization

Not Applicable
Completed
Conditions
Healthy
Volunteers
Interventions
First Posted Date
2017-09-21
Last Posted Date
2017-09-21
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
13
Registration Number
NCT03289559

Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort

Phase 3
Conditions
Fertility Disorders
Interventions
First Posted Date
2017-08-03
Last Posted Date
2017-08-03
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
26
Registration Number
NCT03238092

Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters

Phase 4
Completed
Conditions
Hypogonadism, Male
Interventions
First Posted Date
2017-06-29
Last Posted Date
2021-10-19
Lead Sponsor
University of Miami
Target Recruit Count
60
Registration Number
NCT03203681
Locations
🇺🇸

University of Miami, Miami, Florida, United States

Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

Phase 3
Completed
Conditions
Hypogonadism, Male
Interventions
Drug: SOV2012-F1
Drug: AndroGel
First Posted Date
2017-06-26
Last Posted Date
2023-06-28
Lead Sponsor
Marius Pharmaceuticals
Target Recruit Count
314
Registration Number
NCT03198728
Locations
🇺🇸

Innovative Research of West Florida, Inc., Clearwater, Florida, United States

🇺🇸

Primary Care Research Group, Atlanta, Georgia, United States

🇺🇸

National Clinical Research, Inc., Richmond, Virginia, United States

and more 30 locations
© Copyright 2025. All Rights Reserved by MedPath